Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Official title: A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-03-19
Completion Date
2028-05
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
Tirzepatide
Administered SC
Locations (43)
Medical Dermatology Specialists
Phoenix, Arizona, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Metropolis Dermatology
Los Angeles, California, United States
Northridge Clinical Trials
Northridge, California, United States
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, United States
NeoClinical Research
Hialeah, Florida, United States
Skin Care Research
Hollywood, Florida, United States
Encore Medical Research
Hollywood, Florida, United States
Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research
Tampa, Florida, United States
TruDerm & TruSpa
Wellington, Florida, United States
Southeast Research Specialists
Douglasville, Georgia, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States
Equity Medical - Bowling Green
Bowling Green, Kentucky, United States
Dermatology and Skin Cancer Specialists, LLC
Rockville, Maryland, United States
Metro Boston Clinical Partners
Brighton, Massachusetts, United States
David Fivenson, MD, PLC
Ann Arbor, Michigan, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
The Derm Institute of West Michigan
Caledonia, Michigan, United States
Skin Cancer and Dermatology Institute - Reno
Reno, Nevada, United States
Stracskin
Portsmouth, New Hampshire, United States
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
Care Access - Hoboken
Hoboken, New Jersey, United States
Equity Medical
New York, New York, United States
Revival Research Institute, LLC
Cary, North Carolina, United States
Onsite Clinical Solutions - Huntersville
Huntersville, North Carolina, United States
Optima Research - Boardman
Boardman, Ohio, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Dermatology Associates of Plymouth Meeting
Plymouth Meeting, Pennsylvania, United States
Columbia Dermatology & Aesthetics
Columbia, South Carolina, United States
Alliance for Multispecialty Research, LLC
Myrtle Beach, South Carolina, United States
DelRicht Research - Thompson's Station
Smyrna, Tennessee, United States
Bellaire Dermatology Associates
Bellaire, Texas, United States
Modern Research Associates, PLLC
Dallas, Texas, United States
Center for Clinical Studies
Houston, Texas, United States
Austin Institute for Clinical Research
Pflugerville, Texas, United States
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States
Center for Clinical Studies
Webster, Texas, United States
Tanner Clinic
Layton, Utah, United States
Bellevue Dermatology Clinic
Bellevue, Washington, United States
Dermatology of Seattle
Burien, Washington, United States
Office of Dr. Alma M. Cruz
Carolina, Puerto Rico